Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy

Prostate

Volumn 75, Issue 5, 2015, Pages 550-559

  Henning, Susanne M ^a   Wang, Piwen ^b   Said, Jonathan W ^c   Huang, Min ^e   Grogan, Tristan ^d   Elashoff, David ^d   Carpenter, Catherine L ^a   Heber, David ^a   Aronson, William J ^c,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Bax; Bcl 2; Nuclear factor kappa B; Phase II clinical intervention study

Indexed keywords

ANTIOXIDANT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; POLYPHENOL; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; TUNEL PROTEIN; UNCLASSIFIED DRUG; WATER; 8-OXO-7-HYDRODEOXYGUANOSINE; DEOXYGUANOSINE; PLANT EXTRACT; TEA; TUMOR MARKER;

ADULT; AGED; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BREWING; CANCER GROWTH; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OXIDATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; TEA; ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHYTOTHERAPY; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

ADULT; AGED; APOPTOSIS; BIOMARKERS, TUMOR; DEOXYGUANOSINE; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NF-KAPPA B; PHYTOTHERAPY; PLANT EXTRACTS; POLYPHENOLS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TEA; TREATMENT OUTCOME;

EID: 84923289052     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22943     Document Type: Article

References (41)

1. Sharma V, Rao LJ. A thought on the biological activities of black tea. Crit Rev Food Sci Nutr 2009; 49:379-404.
2. Huang MT, Liu Y, Ramji D., Lo CY, Ghai G, Dushenkov S, Ho CT. Inhibitory effects of black tea theaflavin derivatives on 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and arachidonic acid metabolism in mouse ears. Mol Nutr Food Res 2006; 50:115-122.
3. Sun S, Pan S, Miao A., Ling C, Pang S, Tang J., Chen D, Zhao C. Active extracts of black tea (Camellia Sinensis) induce apoptosis of PC-3 prostate cancer cells via mitochondrial dysfunction. Oncol Rep 2013; 30:763-772.
4. Henning SM, Wang P, Abgaryan N., Vicinanza R, de Oliveira DM, Zhang Y, Lee RP, Carpenter CL, Aronson WJ, Heber D. Phenolic acid concentrations in plasma and urine from men consuming green or black tea and potential chemopreventive properties for colon cancer. Mol Nutr Food Res 2013; 1-14.
5. Henning SM, Wang P, Heber D. Chemopreventive effects of tea in prostate cancer: Green tea versus black tea. Mol Nutr Food Res 2011; 55:1-16.
6. Yang CS, Wang H. Mechanistic issues concerning cancer prevention by tea catechins. Mol Nutr Food Res 2011; 55:819-831.
7. Connors SK, Chornokur G, Kumar NB. New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Nutr Cancer 2012; 64:4-22.
8. Zheng J, Yang B, Huang T., Yu Y, Yang J. Li D. Green tea and black tea consumption and prostate cancer risk: An exploratory meta-analysis of observational studies. Nutr Cancer 2011; 63: 663-672.
9. Lin YW, Hu ZH, Wang X, Mao Q.Q., Qin J., Zheng XY, Xie LP. Tea consumption and prostate cancer: An updated meta-analysis. World J Surg Oncol 2014; 12:38.
10. Bettuzzi S, Brausi M, Rizzi F., Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study. Cancer Res 2006; 66:1234-1240.
11. Nguyen MM, Ahmann FR, Nagle R.B., Hsu CH, Tangrea JA, Parnes HL, Sokoloff M.H., Gretzer MB, Chow HH. Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: Evaluation of potential chemopreventive activities. Cancer Prev Res 2012; 5: 290-298.
12. McLarty J, Bigelow RL, Smith M, Elmajian D., Ankem M, Cardelli J. Tea polyphenols decrease serum levels of prostatespecific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res 2009; 2:673-682.
13. Choan E, Segal R, Jonker D., Malone S, Reaume N, Eapen L., Gallant VA. A prospective clinical trial of green tea for hormone refractory prostate cancer: An evaluation of the complementary/alternative therapy approach. Urol Oncol 2005; 23:108-113.
14. Jatoi A, Ellison N, Burch P.A., Sloan JA, Dakhil SR, Novotny P, Tan W., Fitch TR, Rowland KM, Young CY, Flynn PJ. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003; 97: 1442-1446.
15. Siddiqui IA, Zaman N, Aziz M.H., Reagan-Shaw SR, Sarfaraz S, Adhami V.M., Ahmad N., Raisuddin S, Mukhtar H. Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas. Carcinogenesis 2006; 27:833-839.
16. Hsu A, Bruno RS, Lohr C.V., Taylor AW, Dashwood RH, Bray TM. Ho E. Dietary soy and tea mitigate chronic inflammation and prostate cancer via NFkappaB pathway in the Noble rat model. J Nutr Biochem 2010; 22:502-510.
17. Wang P, Aronson WJ, Huang M, Zhang Y., Lee RP, Heber D. Henning. Green tea polyphenols and metabolites in prostatectomy tissue: Implications for cancer prevention. Cancer Prev Res 2010; 3:985-993.
18. Henning SM, Niu Y, Lee N.H., Thames GD, Minutti RR, Wang H, Go V.L., Heber D. Bioavailability and antioxidant activity of tea flavanols after consumption of green tea, black tea, or a green tea extract supplement. Am J Clin Nutr 2004; 80:1558-1564.
19. Luo H, Tang L, Tang M., Billam M, Huang T, Yu J., Wei Z, Liang Y, Wang K, Zhang ZQ, Zhang L, Wang JS. Phase IIa chemoprevention trial of green tea polyphenols in high-risk individuals of liver cancer: Modulation of urinary excretion of green tea polyphenols and 8-hydroxydeoxyguanosine. Carcinogenesis 2006; 27:262-268.
20. Henning SM, Wang P, Said J., Magyar C, Castor B, Doan N., Tosity C, Moro A, Gao K, Li L, Heber D. Polyphenols in brewed green tea inhibit prostate tumor xenograft growth by localizing to the tumor and decreasing oxidative stress and angiogenesis. J Nutr Biochem 2012; 23:1537-1542.
21. Siddiqui IA, Shukla Y, Adhami V.M., Sarfaraz S., Asim M, Hafeez BB, Mukhtar H. Suppression of NFkappaB and its regulated gene products by oral administration of green tea polyphenols in an autochthonous mouse prostate cancer model. Pharm Res 2008; 25:2135-2142.
22. Gupta S, Ahmad N, Nieminen A.L., Mukhtar H. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol 2000; 164:82-90.
23. Fahy BN, Schlieman MG, Mortenson M.M., Virudachalam S., Bold RJ. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol 2005; 56: 46-54.
24. Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer 2013; 12:86.
25. Ross JS, Kallakury BV, Sheehan C.E., Fisher HA, Kaufman RP, Jr, Kaur P, Gray K, Stringer B. Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: Correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res 2004; 10:2466-2472.
26. Suh J, Payvandi F, Edelstein L.C., Amenta PS, Zong WX, Gelinas C, Rabson AB. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2002; 52:183-200.
27. Sweeney C, Li L, Shanmugam R., Bhat-Nakshatri P, Jayaprakasan V, Baldridge L.A., Gardner T., Smith M, Nakshatri H, Cheng L. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 2004; 10:5501-5507.
28. Jin RJ, Lho Y, Connelly L., Wang Y, Yu X, Saint J.L., Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE, Matusik RJ. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 2008; 68:6762-6769.
29. Lessard L, Mes-Masson AM, Lamarre L., Wall L, Lattouf JB, Saad F NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int 2003; 91:417-420.
30. Wang P, Vadgama JV, Said J.W., Magyar CE, Doan N, Heber D, Henning SM. Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea. J Nutr Biochem 2014; 25:73-80.
31. Shafique K, McLoone P, Qureshi K., Leung H, Hart C, Morrison DS. Tea consumption and the risk of overall and grade specific prostate cancer: A large prospective cohort study of Scottish men. Nutr Cancer 2012; 64:790-797.
32. Montague JA, Butler LM, Wu A.H., Genkinger JM, Koh WP, Wong AS, Wang R. Yuan JM, Yu MC. Green and black tea intake in relation to prostate cancer risk among Singapore Chinese. Cancer Causes Control 2012; 23:1635-1641.
33. Geybels MS, Verhage BA, Arts I.C., van Schooten FJ, Goldbohm RA. Van den Brandt PA. Dietary flavonoid intake, black tea consumption, and risk of overall and advanced stage prostate cancer. Am J Epidemiol 2013; 177:1388-1398.
34. Bardia A, Platz EA, Yegnasubramanian S, De Marzo AM, Nelson WG. Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol 2009; 9:419-426.
35. Ray PD, Huang BW, Tsuji Y Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 2012; 24:981-990.
36. Gupta SC, Hevia D, Patchva S., Park B, Koh W, Aggarwal BB. Upsides and downsides of reactive oxygen species for cancer: The roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal 2012; 16:1295-1322.
37. Li GX, Chen YK, Hou Z, Xiao H., Jin H, Lu G, Lee M.J., Liu B., Guan F, Yang Z, Yu A, Yang CS. Pro-oxidative activities and dose-response relationship of (-)-Epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: A comparative study in vivo and in vitro. Carcinogenesis 2010; 31:902-910.
38. Cooke MS, Olinski R, Loft S. Measurement and meaning of oxidatively modified DNA lesions in urine. Cancer Epidemiol Biomarkers Prev 2008; 17:3-14.
39. Hakim IA, Harris RB, Chow H.H., Dean M., Brown S, Ali IU. Effect of a 4-month tea intervention on oxidative DNA damage among heavy smokers: Role of glutathione S-transferase genotypes. Cancer Epidemiol Biomarkers Prev 2004; 13:242-249.
40. Floriano-Sanchez E, Castro-Marin M, Cardenas-Rodriguez N. Molecular markers associated with prostate cancer: 3-nitrotyrosine and genetic and proteic expression of Mn-superoxide dismutasa (Mn-SOD). Arch Esp Urol 2009; 62:702-711.
41. Henning SM, Aronson W, Niu Y., Conde F, Lee NH, Seeram N.P., Lee RP, Lu J, Harris DM. Tea polyphenols and theaflavins are found in prostate tissue of humans and mice after green and black tea consumption. J Nutr 2006; 136:1839-1143.